Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

One-Two Drug Punch Knocks Down A Lethal Cancer
In the battle against cancer, allies can come from unexpected s. Research at The Jackson Laboratory has yielded a new approach to treating leukemia, one that targets leukemia-proliferating cells with drugs that are already on the market.
generic viagra online
Reform Editorials Examine Rationed Care, Taxing Health Benefits
Wall Street Journal: A recent decision by CMS to end Medicare coverage of virtual colonoscopies is "a preview of how health care will be rationed when Democrats" create "a new "universal" health insurance entitlement for the middle class," a Journal editorial states. According to the editorial, the prospects of such a health system are "playing out in miniature in Medicare" where CMS has decided that offering an alternative to the traditional colonoscopy is "too pricey." The editorial states that the situation features "precisely the sort of complexity that the Democrats would prefer to ignore as they try to restructure health care" and use comparative effectiveness research to determine what works best for the majority of patients. According to the editorial, "The problem is that what "works best" isn"t the same for everyone." It continues that CMS "made the hard-and-fast choice that it was cheaper to cut [virtual colonoscopies] ... for all beneficiaries. If some patients are worse off, well, too bad." The editorial concludes that the situation is "merely a preview of the life-and-death decisions that will be determined by politics" if Democrats enact their ideal system (Wall Street Journal, 5/19).
News of the day
Hitting Cell Hot Spot Could Help Thwart Parkinson's Disease
The latest work to "turn off the taps" in the brain and stop a chemical being released in excess amounts which can lead to Parkinson"s Disease - was presented at The British Pharmacological Society"s Summer Meeting in Edinburgh.
Nutrition

Sepracor Pharmaceuticals Ltd Withdraws Its Marketing Authorisation Application For Lunivia (eszopiclone)

The European Medicines Agency has been formally notified by Sepracor Pharmaceuticals Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Lunivia (eszopiclone), 2 and 3 mg tablets. Lunivia was expected to be used for the treatment of insomnia, including difficulty falling asleep, nocturnal awakening or early awakening in adults, usually for short-term duration. The application for the marketing authorisation for Lunivia was submitted to the Agency on 23 July 2007. In October 2008, Lunivia received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending that the medicine be granted a marketing authorisation. However, the CHMP recommended that the medicine should not be granted "new active substance" status. Following a re÷¬examination procedure at the request of the applicant, the CHMP confirmed its previous opinion in February 2009. At the time of withdrawal, the application was pending the adoption of a marketing authorisation decision by the European Commission. In its official letter, the company stated that the withdrawal of the application was based on the CHMP"s recommendation that Lunivia should not be regarded as containing a new active substance, and that the commercial viability of launching the product in the European Union was compromised. More information about Lunivia and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document, together with the withdrawal letter from the company, will be published on the Agency"s website after the next CHMP meeting of 26-29 May 2009. Notes 1. Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage. 2. The press release from the October 2008 meeting can be found here. 3. The summary of the positive opinion from October 2008 can be found here. EMEA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009